# CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

> **NCT04269213** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 21 (actual)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Secondary Acute Myeloid Leukemia
- Therapy-Related Acute Myeloid Leukemia

## Interventions

- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine

## Key facts

- **NCT ID:** NCT04269213
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-29
- **Primary completion:** 2025-04-10
- **Final completion:** 2027-01-29
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04269213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04269213, "CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04269213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*